The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2025

Filed:

May. 25, 2021
Applicant:

Precision Biosciences, Inc., Durham, NC (US);

Inventors:

Derek Jantz, Durham, NC (US);

James Jefferson Smith, Morrisville, NC (US);

Clayton Beard, Durham, NC (US);

Assignee:

Precision Biosciences, Inc., Durham, NC (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C12N 9/22 (2006.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/40 (2025.01); C07K 14/725 (2006.01); C12N 5/0783 (2010.01); C12N 15/86 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
C12N 9/22 (2013.01); A61K 40/11 (2025.01); A61K 40/31 (2025.01); A61K 40/32 (2025.01); A61K 40/40 (2025.01); C07K 14/7051 (2013.01); C12N 5/0636 (2013.01); C12N 15/86 (2013.01); C12N 15/907 (2013.01); C12N 2750/14143 (2013.01); C12N 2800/60 (2013.01); C12N 2800/80 (2013.01); C12N 2840/20 (2013.01);
Abstract

The present invention provides a genetically-modified T cell comprising in its genome a modified human T cell receptor alpha gene. The modified T cell receptor alpha gene comprises an exogenous sequence of interest inserted into an intron within the T cell receptor alpha gene that is positioned 5' upstream of TRAC exon 1. The exogenous sequence of interest can comprise an exogenous splice acceptor site and/or a poly A signal, which disrupts expression of the T cell receptor alpha subunit. The sequence of interest can also include a coding sequence for a polypeptide, such as a chimeric antigen receptor. Additionally, the endogenous splice donor site and the endogenous splice acceptor site flanking the intron are unmodified and/or remain functional. The invention further provides compositions and methods for producing the genetically-modified cell, and populations of the cell, and methods for the treatment of a disease, such as cancer, using such cells.


Find Patent Forward Citations

Loading…